Efficacy of Anluo Huaxian Pill in Adjuvant Treatment of Chronic HBV Infection Related Cirrhosis and its Effect on Liver Function and Liver Fibrosis
Objective:To investigate the efficacy of Anluo Huaxian Pill in the adjuvant treatment of chronic hepatitis B virus(HBV)infection-related cirrhosis and its effect on liver function and liver fibrosis.Methods:A total of 94 patients with chronic HBV infection-related cirrhosis admitted to our hospital from March 2021 to January 2023 were divided into observation group and control group by random number table method,with 47 patients in each group.Both groups received symptomatic treatment,the control group received entecavir treatment,and the observation group received combined Anluo Huaxian pill adjuvant treatment.The clinical efficacy,liver function,liver fibrosis index and adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After 12 months of treatment,the levels of globulin,alkaline phosphatase,γ-glutamyl transpeptidase,laminin,type IV collagen,type III procollagen and hyaluronic acid in the observation group were lower than those in the control group,and the albumin was higher than that in the control group(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anluo Huaxian pill is effective in the adjuvant treatment of patients with chronic HBV-related cirrhosis,which can effectively improve liver function and liver fibrosis,and has good clinical safety.
Chronic hepatitis B virus infectionAnluo Huaxian pillLiver cirrhosisLiver function
NETL
NSTL
万方数据
